Chapple C R, Christmas T J, Milroy E J
Department of Urology, Middlesex Hospital, London, UK.
Urol Int. 1990;45 Suppl 1:47-55. doi: 10.1159/000282030.
Fifty-eight normotensive patients with benign prostatic hyperplasia and maximum urinary flow rates of less than 15 ml/s were randomly assigned to receive a 12-week course of treatment with prazosin or placebo in a double-blind parallel group trial. Prazosin was administered orally in doses of 0.5 mg and then 1 mg twice daily for 4 days each and 2 mg twice daily for the remainder of the trial. Patients on treatment with prazosin had an increased urinary flow rate as compared to placebo with a significant reduction in maximum voiding detrusor pressure and maximum detrusor pressure at peak urinary flow. Although a significant effect on frequency was not demonstrated, standard parameters of detrusor instability were reduced. Investigators' double-blind overall assessment of efficacy significantly favoured the prazosin treatment. Twelve patients were excluded from the final analysis, 8 being withdrawn because of adverse effects, 5 on treatment with prazosin and 3 in the placebo group. Oral prazosin appears to be safe and effective in the long-term treatment of patients with benign prostatic hyperplasia.
58例血压正常的良性前列腺增生患者，最大尿流率小于15毫升/秒，在一项双盲平行组试验中被随机分配接受为期12周的哌唑嗪或安慰剂治疗。哌唑嗪口服给药，剂量为0.5毫克，然后每天两次，每次1毫克，共4天，在试验剩余时间内每天两次，每次2毫克。与安慰剂相比，接受哌唑嗪治疗的患者尿流率增加，最大排尿逼尿肌压力和尿流峰值时的最大逼尿肌压力显著降低。虽然未显示对尿频有显著影响，但逼尿肌不稳定的标准参数有所降低。研究者对疗效的双盲总体评估明显有利于哌唑嗪治疗。12例患者被排除在最终分析之外，8例因不良反应退出，5例接受哌唑嗪治疗，3例在安慰剂组。口服哌唑嗪在良性前列腺增生患者的长期治疗中似乎是安全有效的。
